<?xml version="1.0"?>
<Articles JournalTitle="Iranian Journal of Public Health">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Iranian Journal of Public Health</JournalTitle>
      <Issn>2251-6085</Issn>
      <Volume>53</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="epublish">
        <Year>2024</Year>
        <Month>06</Month>
        <Day>11</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">The Diagnostic Performance of 68Ga-PSMA-11 PET/MRI for the Biochemically Recurrent Prostate Cancer: A Systematic Review and Meta-analysis</title>
    <FirstPage>1224</FirstPage>
    <LastPage>1235</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Dan</FirstName>
        <LastName>Wang</LastName>
        <affiliation locale="en_US">School of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250014, China</affiliation>
      </Author>
      <Author>
        <FirstName>Zong-Hao</FirstName>
        <LastName>Wang</LastName>
        <affiliation locale="en_US">School of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250014, China</affiliation>
      </Author>
      <Author>
        <FirstName>Chun-Bao</FirstName>
        <LastName>Wang</LastName>
        <affiliation locale="en_US">School of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250014, China</affiliation>
      </Author>
      <Author>
        <FirstName>Zhi-Chun</FirstName>
        <LastName>Wu</LastName>
        <affiliation locale="en_US">School of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250014, China</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2023</Year>
        <Month>10</Month>
        <Day>04</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2023</Year>
        <Month>12</Month>
        <Day>03</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Background: Our meta-analysis aimed to evaluate the diagnostic performance of 68Ga-PSMA-11 PET/MRI for biochemical recurrence of prostate cancer.
&#xD;

Methods: We systematically and comprehensively searched all available studies until May 2023 in the PubMed and Embase databases. Studies evaluating 68Ga-PSMA-11 PET/MRI in men with prostate cancer biochemical recurrence were included. We appraised the quality of studies using a tailored Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool. For each meta-analysis, we used the DerSimonian and Laird method. We first transformed proportions with the Freeman-Tukey double arcsine transformation, and then confidence intervals were calculated using the Jackson method. Meta-regression and sensitivity analysis were conducted to explore heterogeneity sources. Furthermore, we conducted subgroup analysis according to the PSA levels.
&#xD;

Results: Overall, 13 studies with 738 patients were included in the analysis. The pooled overall detection rates of 68Ga-PSMA-11 PET/MRI in detecting recurrent PCa after definitive treatment were 74% (95% CI, 68%-79%). For patients with PSA under 0.5 ng/mL, the detection rate was 55 %. The detection rates were 79 %, 76 % and 87 % for the subgroup PSA levels of 0.5&#x2212;0.99, 1.0&#x2013;1.99 and over 2.0 ng/mL.
&#xD;

Conclusion: 68Ga-PSMA-11 PET/MRI has a good detection rate for biochemical recurrence of prostate cancer. However, large sample, multi-center studies are still needed to verify and expand on our conclusion.</abstract>
    <web_url>https://ijph.tums.ac.ir/index.php/ijph/article/view/33371</web_url>
    <pdf_url>https://ijph.tums.ac.ir/index.php/ijph/article/download/33371/8255</pdf_url>
  </Article>
</Articles>
